Bronchiectasis exacerbation and long-term suppression

01Purpose and principlesWhat the treatment does and how it fits into care.

A bronchiectasis exacerbation is a clinical change, not simply a positive culture or a different sputum colour in isolation. Compare with the individual's daily symptoms and consider viral infection, pneumonia, pulmonary embolism, heart failure, pneumothorax and ABPA when the pattern is atypical. Fever may be absent in advanced disease, while a raised CRP can support severity but cannot identify the pathogen.

Antibiotic selection should be personalised from recent lower-airway microbiology and earlier response. NICE provides empirical choices for non-cystic-fibrosis disease, but Pseudomonas, MRSA, Enterobacterales, intolerance and renal impairment commonly require specialist modification. A rescue pack is useful only when paired with clear start criteria, a sputum-before-first-dose plan and communication with the reviewing team.

Suppression is considered after reversible drivers of frequent attacks have been addressed. Long-term macrolides have the strongest oral evidence for people with repeated exacerbations; inhaled antibiotics are particularly relevant to chronic Pseudomonas infection. NTM disease must be excluded before macrolide monotherapy because resistance can compromise later multidrug treatment.

Key points

An exacerbation is a sustained worsening from the person's baseline in cough, sputum amount or character, purulence, breathlessness, fatigue or haemoptysis that prompts a treatment change.
Before antibiotics, obtain a good sputum sample if possible and retrieve previous stable and attack cultures; previous organisms and susceptibilities are often more informative than a delayed new result.
NICE advises a seven-to-fourteen-day oral course for most adults, chosen from severity, resistance risk, allergy, renal function and microbiology; BTS generally uses fourteen days for Pseudomonas.
Review response and culture results, narrowing or changing treatment when indicated; intravenous antibiotics are considered for severe illness, resistant pathogens or failure of suitable oral therapy.
A first or regrown Pseudomonas isolation with clinical deterioration should trigger specialist discussion of eradication, not automatic acceptance as permanent chronic infection.
Before long-term macrolide treatment, optimise airway clearance, document attack frequency, obtain mycobacterial cultures, assess ECG QTc, liver function, hearing and medicine interactions.
Frequent exacerbators with chronic Pseudomonas may benefit from a specialist-selected inhaled antibiotic; device choice, bronchospasm testing, susceptibility and commissioning vary locally.
Long-term antimicrobial treatment is a monitored trial with a defined outcome and stop review; it creates resistance and adverse effects even when the attack count improves.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Typical infective change

More cough, sputum volume or viscosity, new purulence, breathlessness, wheeze, tiredness or minor haemoptysis evolving over days supports an exacerbation when it represents a clear departure from usual symptoms.

Severe attackRed flag

Marked tachypnoea, low oxygen saturation, hypotension, confusion, inability to maintain intake, respiratory acidosis or rapidly worsening function indicates hospital-level assessment and possible intravenous treatment.

Pneumonia or alternate emergencyRed flag

Focal pleuritic pain, lobar consolidation, disproportionate hypoxaemia, unilateral leg swelling, sudden chest pain or major bleeding should open a broader acute pathway instead of being absorbed into the exacerbation label.

Early treatment failure

Continued fever, breathlessness or purulent sputum after an appropriate initial interval may reflect resistance, poor absorption or adherence, mucus impaction, empyema, obstruction, NTM, fungal disease or a non-infective mimic.

Frequent-exacerbator pattern

Three or more attacks in a year, repeated hospital care, rapid relapse or substantial cumulative antibiotic exposure should prompt prevention review and specialist consideration of suppression rather than serial unexamined rescue courses.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Sputum Gram stain and cultureFirst step
Why
Identify a treatable organism and compare it with the patient's established airway microbiology.
Interpretation and limitations
Collect before the first dose when possible, but begin treatment promptly when unwell. A susceptible result does not guarantee response if drainage is poor; a resistant result needs clinical and microbiology interpretation.
02
Physiological severity assessment
Why
Decide whether outpatient oral care is safe or monitored respiratory support is required.
Interpretation and limitations
Record respiratory rate, oxygen saturation, work of breathing, BP, pulse and mental state. Obtain an arterial blood gas for suspected ventilatory failure or significant hypoxaemia.
03
Chest radiograph
Why
Look for new consolidation, collapse, pleural disease or pneumothorax when symptoms are severe, focal or atypical.
Interpretation and limitations
Chronic bronchial markings may be unchanged. A new infiltrate can represent pneumonia and alters severity and follow-up; a normal film does not rule out an airway exacerbation.
04
FBC, CRP and metabolic profile
Why
Assess systemic inflammation, organ function and antibiotic safety in moderate or severe illness.
Interpretation and limitations
Inflammatory markers help establish trajectory, not microbial identity. Renal and liver results may change antibiotic selection and dose; eosinophilia may redirect attention to ABPA.
05
Mycobacterial sputum before suppression
Why
Avoid inadvertent macrolide monotherapy in unrecognised non-tuberculous mycobacterial pulmonary disease.
Interpretation and limitations
Use adequate samples obtained while the patient is stable and follow the local NTM pathway. A single isolate does not always equal disease, but it must be resolved before a long-term macrolide decision.
06
Pre-macrolide ECG, LFT and sensory history
Why
Identify preventable QT, hepatic, hearing and balance toxicity and relevant interactions.
Interpretation and limitations
A prolonged QTc, interacting QT-prolonging medicines, significant liver abnormality or troublesome auditory or vestibular disease may alter or preclude treatment; use BTS thresholds and local pharmacy review.

04Treatment approachPreparation, options, escalation and aftercare.

01AcuteTreat a community exacerbation safelyFirst stepA clear symptom deterioration without physiological instability or another indication for admission.

1AlternativeCollect sputum, review earlier organisms, allergies, renal function, pregnancy status and recent antibiotic exposure, then select a NICE-listed oral option or organism-directed alternative using local resistance advice.
2Agree a course within the NICE seven-to-fourteen-day range; use a full fourteen-day course for Pseudomonas under BTS practice and individualise duration when illness severity or response justifies it.
3Increase the frequency or adapt the method of airway clearance with physiotherapy advice, maintain hydration and give explicit review triggers for breathlessness, bleeding, fever, confusion or failure to improve.
4EscalationAct on the culture and clinical response, documenting why treatment was continued, narrowed, changed or escalated rather than issuing sequential empirical courses.

02HospitalEscalate severe or resistant infectionEscalationSepsis, respiratory failure, major comorbidity, resistant microbiology, inability to take oral therapy or oral-treatment failure.

1Admit, prescribe oxygen to an appropriate target, send cultures and assess for pneumonia, pleural infection and ventilatory failure while involving respiratory and microbiology teams.
2Choose intravenous antibiotics from recent susceptibilities and local policy; Pseudomonas treatment may require combination or therapeutic-drug-monitoring arrangements that cannot be safely generalised.
3Review intravenous treatment at about forty-eight hours and step down when clinical progress, susceptibility and oral absorption allow; investigate drainage failure or complications if improvement is absent.

03EradicateRespond to new PseudomonasFirst isolation or regrowth of Pseudomonas aeruginosa accompanies clinical deterioration.

1ConfirmatoryDiscuss benefits and burdens with a bronchiectasis specialist and obtain a confirmatory or follow-up sample; distinguish genuine new acquisition from a historical chronic pattern.
2Use the BTS eradication pathway selected for susceptibility, prior exposure and patient factors, observing current MHRA restrictions when a systemic fluoroquinolone is considered.
3Repeat sputum after treatment and during follow-up, recording whether eradication succeeded; ongoing infection moves to chronic-infection risk assessment rather than endless identical eradication courses.

04PreventStart and review long-term suppressionRepeated clinically important attacks continue after airway clearance and underlying drivers have been optimised.

1Confirm the annual attack count and microbiology, revisit adherence, reflux or aspiration, ABPA and immune disease, and agree the outcome that would make long-term treatment worthwhile.
2For a macrolide, exclude active NTM, obtain ECG and LFT, counsel about gastrointestinal, auditory, cardiac and resistance risks, and use a BTS evidence-based schedule through specialist care.
3For chronic Pseudomonas, assess a commissioned inhaled antibiotic with supervised tolerance testing and device training; continue physiotherapy rather than allowing nebulised treatment to replace clearance.
4Review attacks, symptoms, cultures, toxicity and burden at defined intervals, stopping or changing therapy if benefit is absent or harm outweighs it.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

A first-choice empirical oral option for some adults without higher risk of treatment failure, then refined against current microbiology.

Amoxicillin for a susceptible uncomplicated exacerbation

NICE lists 500 mg orally three times daily for 7 to 14 days; use previous culture, severity and local guidance to decide whether this narrow-spectrum option is appropriate.

Check immediate and severe delayed penicillin allergy, renal function and recent organisms. It does not cover Pseudomonas and should not be continued blindly when culture, deterioration or previous resistance indicates another choice.

Reduces exacerbation frequency in selected adults, commonly those with three or more attacks per year after standard care is optimised.

Azithromycin for specialist long-term suppression

BTS-supported regimens include 500 mg orally three times weekly or 250 mg daily; a lower 250 mg three-times-weekly start may reduce adverse effects, with response-led specialist adjustment.

Exclude NTM pulmonary disease first. Check ECG QTc, LFT, hearing and balance history, interactions and antimicrobial-resistance implications; repeat safety testing under the BTS schedule and reassess ongoing need.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

During an attack, track breathlessness, sputum, temperature, oxygenation and ability to eat and clear secretions; arrange earlier review when the baseline disease is severe.
Check culture and susceptibility results actively rather than assuming the laboratory will trigger a treatment change, and document the clinical response at course completion.
For long-term antibiotics, count protocol-defined exacerbations, hospital admissions and rescue courses over a comparable period and record quality-of-life or sputum goals agreed before treatment.
Repeat ECG and liver tests after macrolide initiation according to BTS guidance, and ask specifically about tinnitus, hearing change, imbalance, palpitations and gastrointestinal intolerance.
Continue periodic routine and mycobacterial sputum surveillance during suppression, watching for new resistance, Pseudomonas, NTM or fungal disease and revisiting the regimen with microbiology.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Culture before the cupboard

A home rescue pack is safest when the patient knows to produce sputum first, start only for an agreed symptom pattern and notify the service so results and attack counts are captured.

Purulence is useful but not sovereign

Colour change supports neutrophilic airway inflammation, yet viral infection, ABPA and chronic daily purulence complicate interpretation; compare the whole symptom cluster with baseline.

Macrolides can mask mycobacteria

Long-term single-agent exposure may select macrolide-resistant NTM, removing a central component of later multidrug therapy; pre-treatment sampling is therefore a safety action, not paperwork.

Nebulised is still systemic work

Inhaled antibiotics add preparation, cleaning, bronchospasm and adherence burdens. A supervised challenge and a clearly measured benefit protect against years of ineffective treatment.

08Common pitfallsFrequent interpretation and management errors.

01
Treating every positive stable sputum result as an acute infection without a change from baseline symptoms.
02
Choosing an empirical antibiotic without checking the patient's previous Pseudomonas or resistant-organism history.
03
Repeating short courses for Pseudomonas despite BTS advice for a full course and specialist-directed treatment.
04
Starting long-term azithromycin before mycobacterial cultures, ECG, liver tests and interaction review.
05
Continuing suppressive antibiotics indefinitely without documenting fewer attacks, tolerability, resistance and a formal stop decision.